Mankind Pharma share price
NSE: MANKINDBSE: 543904Pharmaceuticals & BiotechnologyMid Cap
Mankind Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2023 · Issue price ₹1,080
Last close ₹2,490.00down ₹12.50 (0.50%)BSE ₹2,483.60
Share price at the NSE close on 28 Oct 2026. Previous close ₹2,502.50.
28 Oct: open ₹2,496.60, high ₹2,549.00, low ₹2,477.40
52-week range of traded prices to 28 Oct 2026
₹1,909.70Low, 23 Mar 2026₹2,642.00High, 29 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,02,848 Cr119th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 45.74
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.85
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.30
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 10,86,41051.5% delivered
About Mankind Pharma
Mankind Pharma develops, makes and sells medicines in India for short-term (acute) and long-term (chronic) conditions, including infections, heart disease, diabetes, digestive and women's health disorders, along with consumer health products such as condoms, pregnancy tests and antacids.1 Its subsidiary Bharat Serums and Vaccines (BSV) sells specialty medicines for women's health, fertility and critical care in India and abroad.234
It reports a single business segment, pharmaceuticals, and describes the business as 4 parts: its base business, specialty chronic medicines, over-the-counter consumer health and the BSV portfolio.56 It sells through a field force of over 18,500 people who reach more than 5 lakh doctors, and through more than 17,600 stockists (wholesale distributors).7
It was incorporated in 1991 and has grown from a sales and marketing company into one that also researches and makes its own medicines.89 Its shares were listed on the NSE and BSE on 9 May 2023, after an initial public offer.10 It acquired BSV on 23 Oct 2024 for a purchase consideration of ₹13,768.22 crore.1112 On 18 Mar 2026 it bought the India rights to Rivotril, a clonazepam brand for neurological and psychiatric conditions, from Roche.13 It has also bought brands from Panacea Biotec, which took it into transplant and cancer medicines, and the Daffy and Combihale brands.14
Its promoters are Ramesh Juneja, the Executive Chairman, his brother Rajeev Juneja, Vice Chairman and Managing Director, and Sheetal Arora, Chief Executive Officer, who hold shares directly and through family trusts.1516
Mankind Pharma key points
Results
- Revenue was ₹4,031 crore in the quarter to Jun 2026, up 13%, and EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹1,060 crore, a 26.3% margin.17
- Profit after tax was ₹574 crore in the quarter to Jun 2026, up 29.1%, and its margin on revenue rose to 14.2% from 12.5%.18
- In the year to Mar 2026, consolidated revenue rose 17% to ₹14,278 crore from ₹12,207 crore, and EBITDA rose 15.5% to ₹3,499 crore, a 24.5% margin against 24.8%.19
- Consolidated profit after tax fell 3.4% to ₹1,938 crore in the year to Mar 2026 from ₹2,007 crore, on higher depreciation and finance costs and lower other income.20
Market position
- In the year to Mar 2026 it was India's 4th largest pharmaceutical company by value, with a 4.7% market share, and 2nd largest by volume, with 6.1%.21
- It has ranked 1st in India by doctors' prescriptions for 9 years, with a 15.2% share in the quarter to Jun 2026.2223
- After buying BSV it became the largest company in gynaecology (women's health), with a 10.3% market share in the year to Mar 2026.24
- Consumer brand market share by category, year to Jun 2026252627Its brand ranks 1st in each except antacid powders (2nd), pain management (5th) and vitamins, minerals and nutrients (8th).
Item year to Jun 2026 Pregnancy test kits 84% Emergency contraceptives 68% Medicated anti-acne products 34% Condoms 28% Antacid powders 12% Vitamins, minerals and nutrients 2.3% Pain management 1.3%
Revenue mix
- Revenue by business, quarter to Jun 202628
Item quarter to Jun 2026 quarter to Jun 2025 Domestic, excluding consumer healthcare ₹3,180 crore ₹2,864 crore Exports ₹605 crore ₹469 crore Consumer healthcare ₹246 crore ₹237 crore - In the year to Mar 2026, domestic revenue rose 14.4% to ₹12,217 crore and international revenue 34.5% to ₹2,061 crore; organic growth (from the business it already owned) was 8.6% in each, the rest from a full year of BSV.29
Plants and capacity
- It has 32 manufacturing facilities with an installed capacity of over 44 billion units, and makes over 75% of its production in-house.3031
- Its Udaipur and Ambernath plants received EU GMP certification (the European Union's manufacturing quality standard) in the year to Mar 2026.32
- As of its annual report of 9 Jul 2026, it was setting up a biologics (medicines made from living cells) plant at Vadodara and had started commercial production on an expanded biologics line at Ambernath.33
Research and development
- It has 7 research and development (R&D) centres with over 740 scientists, and spent 2.8% of revenue on R&D in the year to Mar 2026, against 2.2% a year earlier.3034
- Medicines in development, as of the annual report of 9 Jul 20263536Phase I to III are the stages of testing a medicine in people before approval; a biosimilar is a close copy of a biological medicine.
Item year to Mar 2026 GPR-119, its first in-house new molecule, for obesity Advanced Phase II Immune-signal blocker (JAK inhibitor) for autoimmune diseases Phase I Insulin Aspart Phase III completed, nearing launch in India IVF (in vitro fertilisation) biosimilar, the first in India Moving to Phase III
What the company expects
- On its earnings call of 30 Jul 2026, the company said it expects double-digit domestic growth and gross margins (sales less the cost of goods, as a share of sales) above 71% in the year to Mar 2027, though margins may narrow next quarter.3738
- On its earnings call of 30 Jul 2026, the company said its chronic share (sales of medicines for long-term conditions), excluding BSV, is about 40% and it sees potential to move towards 50% over the next 4 to 5 years.3940
- On its earnings call of 30 Jul 2026, the company said it is on track to repay its acquisition debt by the year to Mar 2028; net debt (borrowings less cash) was ₹3,377 crore at the end of June 2026.4142
Recent events
- On 15 Oct 2026 it agreed, through a Dutch subsidiary, to invest €48 million, in instalments, for a 70% stake in Armed Cell Therapeutics, a Belgian company developing CAR-T therapies (immune cells engineered to attack cancer).4344
- On 26 Aug 2026 its board approved folding its wholly owned subsidiary Bharat Serums and Vaccines into the company through voluntary liquidation, subject to approvals.45
- On 20 Aug 2026 it signed an exclusive licence with Chongqing Chenan Biopharmaceutical of China to sell 2 insulins in India, Insulin Degludec and Insulin Degludec with Aspart.46
Litigation and regulatory matters
Last updated
All 48 sources, each with its page
- 1. Annual report, 9 Jul 2026, page 71
- 2. Annual report, 9 Jul 2026, page 33
- 3. Annual report, 9 Jul 2026, page 21
- 4. Annual report, 9 Jul 2026, page 101
- 5. Annual report, 9 Jul 2026, page 276
- 6. Annual report, 9 Jul 2026, page 74
- 7. Annual report, 9 Jul 2026, page 71
- 8. Annual report, 9 Jul 2026, page 105
- 9. Annual report, 9 Jul 2026, page 25
- 10. Annual report, 9 Jul 2026, page 142
- 11. Annual report, 9 Jul 2026, page 73
- 12. Annual report, 9 Jul 2026, page 284
- 13. Exchange filing, 18 Mar 2026, page 2
- 14. Investor presentation, 30 Jul 2026, page 17
- 15. Annual report, 9 Jul 2026, page 91
- 16. Annual report, 9 Jul 2026, page 164
- 17. Earnings call, 30 Jul 2026, page 3
- 18. Earnings call, 30 Jul 2026, page 6
- 19. Annual report, 9 Jul 2026, page 73
- 20. Annual report, 9 Jul 2026, page 73
- 21. Annual report, 9 Jul 2026, page 71
- 22. Investor presentation, 30 Jul 2026, page 9
- 23. Earnings call, 30 Jul 2026, page 5
- 24. Annual report, 9 Jul 2026, page 74
- 25. Investor presentation, 30 Jul 2026, page 13
- 26. Investor presentation, 30 Jul 2026, page 13
- 27. Investor presentation, 30 Jul 2026, page 13
- 28. Investor presentation, 30 Jul 2026, page 6
- 29. Annual report, 9 Jul 2026, page 73
- 30. Annual report, 9 Jul 2026, page 71
- 31. Annual report, 9 Jul 2026, page 23
- 32. Annual report, 9 Jul 2026, page 33
- 33. Annual report, 9 Jul 2026, page 48
- 34. Annual report, 9 Jul 2026, page 23
- 35. Annual report, 9 Jul 2026, page 42
- 36. Annual report, 9 Jul 2026, page 23
- 37. Earnings call, 30 Jul 2026, page 8
- 38. Earnings call, 30 Jul 2026, page 17
- 39. Earnings call, 30 Jul 2026, page 7
- 40. Earnings call, 30 Jul 2026, page 4
- 41. Earnings call, 30 Jul 2026, page 6
- 42. Earnings call, 30 Jul 2026, page 6
- 43. Exchange filing, 15 Oct 2026, page 4
- 44. Exchange filing, 15 Oct 2026, page 2
- 45. Exchange filing, 26 Aug 2026, page 1
- 46. Exchange filing, 20 Aug 2026, page 2
- 47. Annual report, 9 Jul 2026, page 172
- 48. Annual report, 9 Jul 2026, page 172
Results
Consolidated; ₹ crore.Mankind Pharma quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +13.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +28.4%
Quarter to Sep 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹4,338 Crup 7.62%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹716 Crup 24.74%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 16.5%
Revenue by quarter
Peak revenue ₹4,338 Cr, quarter to Sep 2026; lowest ₹3,079 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,230 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 | 4,031 | 4,338 |
| Net profit | 385 | 425 | 445 | 520 | 414 | 559 | 574 | 716 |
| Net margin | 11.9% | 13.8% | 12.5% | 14.1% | 11.6% | 16.2% | 14.2% | 16.5% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹14,278 Crup 16.96%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,938 Crdown 3.63%
- Net margin
- 13.6%
Revenue by year
Peak revenue ₹14,278 Cr, year to Mar 2026; lowest ₹8,749 Cr, year to Mar 2023
Net profit by year, a loss in red
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 8,749 | 10,335 | 12,207 | 14,278 |
| Net profit | 1,310 | 1,942 | 2,011 | 1,938 |
| Net margin | 15.0% | 18.8% | 16.5% | 13.6% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.Mankind Pharma PE ratio and valuation
Price to earnings
At or below today's level on 10% of 672 trading days since Feb 2024.
LowestHighest
Its median50.41Industry median27.98
Price to book
At or below today's level on 10% of 744 trading days over the last 3 years.
LowestHighest
Its median8.66Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 67% of 744 trading days over the last 3 years.
LowestHighest
Its median0.00%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −17.2% | −5.9% | −12.0% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
226 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 89 of the 122 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 226 funds holding Mankind Pharma
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 66
- CutCut. Funds that held fewer shares than at the end of the month before.
- 56
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 96
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 11
| Fund | |||
|---|---|---|---|
 SBI Large Cap FundSBI Mutual Fund | 40,72,930 | 1.95% | ₹1,019.8 Cr |
 Nippon India Growth Mid Cap FundNippon India Mutual Fund | 39,00,000 | 1.95% | ₹976.5 Cr |
 HDFC Large Cap FundHDFC Mutual Fund | 27,39,492 | 1.84% | ₹685.9 Cr |
| Nippon India Large Cap FundNippon India Mutual Fund | 21,34,592 | 1.04% | ₹534.5 Cr |
 Aditya Birla Sun Life Flexi Cap FundAditya Birla Sun Life Mutual Fund | 20,72,385 | 1.85% | ₹518.9 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 16,03,562 | 4.38% | ₹401.5 Cr |
 Franklin India Opportunities FundFranklin Templeton Mutual Fund | 15,21,556 | 3.98% | ₹381.0 Cr |
| Aditya Birla Sun Life Large Cap FundAditya Birla Sun Life Mutual Fund | 15,10,424 | 1.35% | ₹378.2 Cr |
 HSBC Midcap FundHSBC Mutual Fund | 14,92,496 | 2.22% | ₹373.7 Cr |
 Mirae Asset Midcap FundMirae Asset Mutual Fund | 14,31,251 | 1.83% | ₹358.4 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Mankind Pharma insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade · 11 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Mankind Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Mankind Pharma in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Laurus LabsLAURUSLABS | 1,17,891 | 107.82 | 22.24 | +22.6% | +114.9% | 22.4% | 19.8% | 0.09% |
 Zydus LifesciencesZYDUSLIFE | 1,17,257 | 25.98 | 4.33 | +21.1% | −1.3% | 17.7% | 15.9% | 0.09% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,11,463 | 39.81 | 2.87 | −3.5% | −51.5% | 7.5% | 6.0% | 0.60% |
 CiplaCIPLA | 1,10,323 | 38.08 | 3.12 | −0.7% | −46.8% | 8.5% | 9.7% | 0.95% |
 Aurobindo PharmaAUROPHARMA | 94,638 | 25.49 | 2.50 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 LupinLUPIN | 90,210 | 16.32 | 4.02 | +28.2% | +49.5% | 27.9% | 28.2% | 0.91% |
 Glenmark PharmaceuticalsGLENMARK | 64,912 | 36.10 | 6.17 | +32.9% | +138.4% | 18.6% | 39.8% | 0.11% |
 Alkem LaboratoriesALKEM | 60,619 | 28.10 | 4.39 | +13.4% | −5.6% | 16.7% | 16.5% | 1.05% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Mankind Pharma dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹1.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 8 Aug 2025 | Interim | ₹1.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Mankind Pharma announcements
Oct 2026
26 Oct · Results
22 Oct · Analysts
22 Oct · Analysts
15 Oct
Mankind Pharma share price by year
Each calendar year to 2025.Mankind Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 2,196.50 | −23.7% | 2,937.55 | 2,106.00 |
| 2024 | 2,880.40 | +45.3% | 2,998.40 | 1,979.20 |
| 2023 | 1,982.50 | – | 2,012.90 | 1,322.65 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 9 May 2023.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 2,358.50 | 2,529.80 | 2,352.10 | 2,502.50 | 2,478.03 | 30,30,899 | 22.4% |
| 26 Oct 2026 | 2,223.70 | 2,333.90 | 2,215.00 | 2,312.00 | 2,272.54 | 10,25,428 | 44.5% |
| 23 Oct 2026 | 2,282.90 | 2,289.60 | 2,196.10 | 2,212.60 | 2,219.19 | 6,79,106 | 61.7% |
| 22 Oct 2026 | 2,266.00 | 2,299.60 | 2,233.60 | 2,275.60 | 2,263.23 | 6,49,740 | 52.8% |
| 21 Oct 2026 | 2,256.20 | 2,285.50 | 2,243.10 | 2,285.50 | 2,258.45 | 2,46,631 | 57.3% |
| 19 Oct 2026 | 2,264.10 | 2,348.50 | 2,246.00 | 2,253.20 | 2,288.79 | 12,28,705 | 59.9% |
| 16 Oct 2026 | 2,349.90 | 2,354.40 | 2,268.70 | 2,275.50 | 2,289.28 | 8,89,731 | 61.7% |
| 15 Oct 2026 | 2,325.60 | 2,365.00 | 2,321.10 | 2,347.60 | 2,353.57 | 6,45,492 | 61.4% |
| 14 Oct 2026 | 2,372.00 | 2,372.00 | 2,317.50 | 2,335.00 | 2,335.36 | 4,98,158 | 59.1% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- MANKIND
- BSE code
- 543904
- ISIN
- INE634S01028
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.mankindpharma.com
- CIN
- L74899DL1991PLC044843
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1991
- Registered office
- 208, Okhla Industrial Estate , Phase-III, New Delhi 110020, Delhi
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 200, BSE 200, Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index